---
document_datetime: 2024-07-09 15:26:51
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/duloxetine-lilly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: duloxetine-lilly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.3714021
conversion_datetime: 2025-12-23 07:51:58.083643
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Duloxetine Lilly

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1187/ 202308   | Periodic Safety Update EU Single assessment - duloxetine                                                                                               | 25/04/2024                          | 20/06/2024                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1187/202308. |
| IG/1625              | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect | 17/08/2023                          | n/a                                         |                                  |                                                                                                                                           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |    |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| WS/2220/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                               | 10/03/2022 | n/a        |    |                                   |
| N/0024             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                | 15/12/2021 | 20/06/2024 | PL |                                   |
| PSUSA/1187/ 202008 | Periodic Safety Update EU Single assessment - duloxetine                                                                                                                                                                                                                                                                                                                                                                                                                        | 11/03/2021 | n/a        |    | PRAC Recommendation - maintenance |
| IG/1355/G          | This was an application for a group of variations. B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - | 24/02/2021 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Updated certificate manufacturer B.III.1.b.3 - Submission deletion of Ph. Eur. Updated certificate manufacturer B.III.1.b.4 - Submission deletion of Ph. Eur. Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. Deletion of certificates exist per material)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| WS/1879   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. This worksharing variation is being submitted to present and discuss the results of Study F1J-MC- B034 Pregnancy Registry to meet the commitment made during the previous procedure No. EMEA/H/C/WS1527/G which received positive CHMP opinion on 25 July 2019. As a consequence of the submission of the F1J-MC- B034 Study Report, the Risk Management Plan (RMP) for duloxetine has been updated. The RMP for all Lilly duloxetine products are combined. The changes introduced are not specific to one product and are therefore the same for all products. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission   | 03/09/2020   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1755   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. As agreed in the procedure WS-1527G in order to address the foetal outcomes, submission of the final report from study FIJ-MC-B059 'Observational Study to Assess Fetal Outcomes Following Maternal                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11/06/2020   | 17/06/2021 | SmPC and PL | As agreed in the procedure WS-1527G in order to address the foetal outcomes, submission of the final report from study FIJ-MC-B059 'Observational Study to Assess Fetal Outcomes Following Maternal Exposure to Duloxetine' and the revised final report from study Study F1J - MC - B057 'Observational Studies to Assess Maternal and Fetal Outcomes Following Exposure to Duloxetine'. |

<div style=\"page-break-after: always\"></div>

|         | Exposure to Duloxetine' and the revised final report from study Study F1J - MC - B057 'Observational Studies to Assess Maternal and Fetal Outcomes Following Exposure to Duloxetine'. Section 4.6 of the SmPc and section 2 of the PL were updated to reflect the available knowledge with regard to the usBe of duloxetine during pregnancy. The MAH took also the opportunity to include the declaration of sodium in the Product Information following the guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. During the assessment and following a transfer of MAH, Xeristar was removed from the WS procedure. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission   |            |            |                        | Section 4.6 of the SmPc and section 2 of the PL were updated to reflect the available knowledge with regard to the usBe of duloxetine during pregnancy. The MAH took also the opportunity to include the declaration of sodium in the Product Information following the guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. During the assessment and following a transfer of MAH, Xeristar was removed from the WS procedure.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1134 | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/08/2019 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0015  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/05/2019 | 31/07/2019 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Duloxetine Lilly in the approved indication remains favourable and therefore recommended the renewal of the                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        | marketing authorisation with unlimited validity.                                                                                                                                                                                              |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1126   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 25/07/2019 | 12/06/2020 | SmPC and PL            |                                                                                                                                                                                                                                               |
| WS/1527/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z (Type IB) - to stop enrolment of Study F1J- MC-B034 (study B034), another study included in the current EU-RMP as an additional pharmacovigilance activities to address missing information regarding duloxetine exposure due to pregnancy. C.I.4 (Type II) - Update of sections 4.4, 4.6 and 4.8 of the SmPC in order to add a warning on the risk of postpartum haemorrhage based on final results from study Study F1J - MC - B057 listed as a category 3 in the RMP; this is an observational study to assess maternal and foetal outcomes following exposure to duloxetine. The Package Leaflet is updated accordingly. | 25/07/2019 | 12/06/2020 | SmPC, Labelling and PL | Observational data have provided evidence of an increased risk (less than 2 -fold) of postpartum haemorrhage following duloxetine exposure within the month prior to birth. This risk is now reflected in the SmPC sections 4.4, 4.6 and 4.8. |
|           | The RMP version 13 has also been submitted. In addition, the Worksharing applicant (WSA) took the opportunity to correct the term 'sucrase - isomaltase' in section 4.4 of the SmPC in line with the Annex to the EC guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (EMA/CHMP/302620/2017 corr. 1*) and to bring the PI in line with the latest QRD                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        |                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|         | The Xeristar 30 mg SmPC & Xeristar 60 mg SmPC and the Yentreve 20 mg SmPC & Yentreve 40 mg SmPC have been combined in a single SmPC, respectively, following the Policy on combined SmPCs (EMA/333423/2015). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing including the RMP - Other variation   |            |            |      | template version 10. authorisation,   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------|
| WS/1598 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH                                                                            | 14/06/2019 | 12/06/2020 | SmPC |                                       |
| WS/1619 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                              | 06/06/2019 | n/a        |      |                                       |

<div style=\"page-break-after: always\"></div>

| IG/1055            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 18/01/2019   | 31/07/2019   | SmPC and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0996            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23/10/2018   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PSUSA/1187/ 201708 | Periodic Safety Update EU Single assessment - duloxetine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 12/04/2018   | n/a          |               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| WS/1264            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of the final report from study F1J-MC- B056 listed as a category 3 study in the RMP. This is a non-interventional non-imposed study aimed to investigate the association between duloxetine exposure and suicide-related behaviours and ideation in women with stress urinary inconsistence (SUI). The RMP version 12.4 has also been updated to reflect the study results. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 08/02/2018   | n/a          |               | The association between suicide attempts and receipt of duloxetine treatment in women with stress urinary inconsistence (SUI) compared to women with SUI without duloxetine treatment has been assessed in study F1J-MC- B056. Study B056 has several limitations but in the light of the results the association between the risk of suicidality and duloxetine treatment cannot be completely ruled out. Currently, the risk of suicidality is an important identified risk for duloxetine-containing products and adequate warnings concerning this risk are already included in the SmPC. No further changes to the product information are warranted. The RMP is updated to reflect the study results and limitations and update the pharmacovigilance plan regarding this study. |
| WS/1331            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the                                                                                                                                                                                                                                                                                                                                                                                                                            | 01/02/2018   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | to comply with the provisions of an updated monograph of the Ph. Eur. for the finished                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                                  | dossier general product   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------|
| WS/1109   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 26/01/2017 | 20/12/2017 | SmPC, Annex II, Labelling and PL |                           |
| IG/0759/G | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or | 11/01/2017 | n/a        |                                  |                           |

<div style=\"page-break-after: always\"></div>

|         | of Ph. Eur. TSE Certificate of Suitability - certificate from an already approved                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                        | deletion Updated manufacturer   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------|
| WS/1015 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To update the RMP to add a new Observational Study to Assess Maternal and Fetal Outcomes Following Exposure to Duloxetine (F1J-MC-B057), and to update the plans for the existing pregnancy registry (F1JMC-B034) in section III.4.3 of the RMP. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH | 13/10/2016 | n/a        |                        |                                 |
| IG/0664 | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                           | 25/02/2016 | n/a        |                        |                                 |
| IG/0662 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 23/02/2016 | 04/07/2016 | SmPC, Labelling and PL |                                 |
| IB/0002 | C.I.3.z - Change(s) in the SPC, Labelling or PL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 21/07/2015 | 04/07/2016 | SmPC and PL            |                                 |

<div style=\"page-break-after: always\"></div>

|         | intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| WS/0758 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC in order to add microscopic colitis with frequency category 'rare' as a new ADR identified from post marketing experience. The Package Leaflet is updated accordingly. In addition, the Worksharing applicant took the opportunity to make minor editorial changes in the SmPC and PL and to update the local representative for Italy in the Package Leaflet for Xeristar. Moreover, the Worksharing applicant took the opportunity to correct the stated mass of sucrose in capsule in section 2 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 09/07/2015 | 04/07/2016 | SmPC and PL |